Cellectar’s CLR 131 Receives Fourth RPDD
Cellectar Biosciences’ CLR 131 has been granted a Rare Pediatric Disease Designation (RPDD) for the treatment of osteosarcoma, the company announced recently. “Cellectar is pleased to have the opportunity to…
Category Archives: Biotech
Phoenix to Build Facility in Fitchburg
Phoenix, which designs and manufactures the world’s strongest neutron generators, is building a neutron imaging center in Fitchburg, Wis., the company announced recently. According to a release, the 10,000-square foot building,…
Exact Sciences, Pfizer Form Agreement
Exact Sciences and Pfizer announced today an agreement to co-promote Cologuard through 2021. According to a release, Pfizer will join Exact Sciences’ sales representatives in reaching both physicians and health…
Propeller Health, Anthem Collaborate
Propeller Health announced recently that it’s collaborating with Anthem Blue Cross and Blue Shield to help improve health outcomes for Ohio consumers enrolled in Anthem’s Medicare Advantage health plans who have…
Exact Sciences Breaks Ground at Innovation One
Exact Sciences broke ground on its new corporate headquarters building at University Research Park, calling it Innovation One, the company announced recently. According to a release, the 138,000 square-foot building,…
Cellectar’s CLR 131 Receives RPDD
Cellectar Biosciences’ CLR 131 has been granted a Rare Pediatric Disease Designation (RPDD) for the treatment of Ewing’s sarcoma, a rare pediatric cancer, by The U.S. Food and Drug Administration…
Cellectar Closes $16.56M Public Offering
Cellectar Biosciences today announced the effective prices of $4.00 per share of common stock of an underwritten public offering to raise approximately $16.56 million. According to a release, this includes the full…
Exact Sciences Focusing on Community, Staff
The Madison community is important to the success of Exact Sciences, CEO Kevin Conroy said at the annual shareholder meeting held today at the Edgewater Hotel. “If you have a…
Cellectar Reports Positive Data in Cancer Trial
Cellectar Biosciences announced today a patient, enrolled in the CLR 131 Phase 2 trial, showed a 94 percent reduction in tumor burden and complete resolution in four of five targeted…
Gregor Diagnostics Raises $900K
Gregor Diagnostics, a molecular diagnostics company developing an at-home screening test for prostate cancer, closed a $900,000 round of seed financing, the company announced recently. According to a release, the…
